The FDA has approved Yuvezzi (carbachol and brimonidine tartrate), a once-daily eye drop to treat presbyopia in adults. Last year, the FDA approved a single-agent therapy, VIZZ (acedidine), a once-daily eye drop for adults with presbyopia. The phase 3 BRIO I study demonstrated the benefit of the combination therapy over the individual components, which is a requirement for FDA approval of a fixed-dose combination. The most common adverse events were headache, impaired vision, and temporary eye pain or eye irritation. In BRIO II, the rate of reported eye redness was lower in patients receiving Yuvezzi than in those receiving carbachol alone.